Sponsored Links
| Pharmasset Announces The Expansion Of The ELECTRON Trial In Chronic Hepatitis C |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Pharmasset, Inc. (Nasdaq: VRUS) announced the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The rapid and consistent antiviral effects and high barrier to resistance demonstrated with PSI-7977 to date provide the rationale for additional exploratory regimens in this setting... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|